When do the patents on TRAVASOL 8.5% W/O ELECTROLYTES expire, and when will TRAVASOL 8.5% W/O ELECTROLYTES go generic?

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Baxter Hlthcare	TRAVASOL 8.5% W/O ELECTROLYTES	amino acids	INJECTABLE;INJECTION	017493-005	Approved Prior to Jan 1, 1982		DISCN	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Last updated: October 7, 2026

TRAVASOL 8.5% Without Electrolytes is a prescription amino-acid injection used as a component of parenteral nutrition. Its commercial position is driven by hospital demand, intensive-care utilization, nutrition-support protocols, manufacturing capacity, and supply reliability rather than by patent exclusivity. Baxter Healthcare is the principal marketed supplier identified in U.S. product labeling. Product-specific revenue is not separately disclosed in Baxter’s public filings, so financial analysis must rely on the broader parenteral-nutrition and hospital-products businesses.

What is TRAVASOL 8.5% Without Electrolytes?

TRAVASOL 8.5% is an intravenous amino-acid solution containing essential and nonessential amino acids in water for injection. The formulation does not contain electrolytes, allowing clinicians to add electrolytes and other nutrients according to the patient’s clinical requirements.

The product is used as part of total parenteral nutrition, or TPN, when oral or enteral nutrition is inadequate, contraindicated, or not possible. It is not a complete parenteral-nutrition formulation by itself. Dextrose, lipid emulsion, electrolytes, vitamins, trace elements, and other components are generally added based on individual nutritional needs.

Attribute	TRAVASOL 8.5% Without Electrolytes
Active component	Crystalline amino acids
Strength	8.5%
Electrolytes	None in the labeled formulation
Route	Intravenous infusion
Primary use	Parenteral nutrition
Product type	Sterile injectable
Primary U.S. marketer	Baxter Healthcare Corporation
Regulatory pathway	FDA-approved prescription drug
Patent dependence	Low
Principal commercial risks	Manufacturing disruption, hospital purchasing pressure, shortages, substitution

FDA labeling states that the product is intended for patients requiring parenteral nutrition and that administration should be guided by nitrogen balance, fluid status, glucose tolerance, and electrolyte measurements (Baxter Healthcare Corporation, 2021).

What is the FDA and Orange Book status of TRAVASOL?

TRAVASOL 8.5% Without Electrolytes is an FDA-approved prescription injectable. It is not a new molecular entity and does not depend on market exclusivity associated with a novel active pharmaceutical ingredient.

The product’s commercial protection is primarily regulatory and operational:

FDA approval for the labeled formulation and presentation.
Establishment-specific manufacturing controls.
Sterile injectable production capability.
Hospital formulary placement.
Customer familiarity and supply history.
Contracting and distribution relationships.

The product is not generally viewed as an Orange Book-driven asset. Its competitive position does not depend on a late-stage patent listed against a novel active ingredient. FDA’s Orange Book framework is most commercially important for products with listed patents and abbreviated new drug application, or ANDA, challenges. For established amino-acid injections, generic and therapeutically substitutable competition is more likely to arise through approved sterile-injectable products, private-label supply, and competing manufacturers than through a high-value Paragraph IV campaign (U.S. Food and Drug Administration, 2024a).

What patents protect TRAVASOL 8.5%?

No material composition-of-matter patent estate is associated with the amino-acid formulation as a mature parenteral-nutrition product. The amino acids are established pharmaceutical ingredients, and the formulation category has been marketed for decades.

Potentially relevant intellectual-property categories include:

IP category	Relevance to TRAVASOL 8.5%
Composition-of-matter patents	No meaningful commercial barrier expected
Formulation patents	Limited relevance for a conventional amino-acid solution
Method-of-use patents	Limited; parenteral nutrition use is established
Container patents	May protect specific bags, ports, or packaging systems
Manufacturing know-how	Important for sterility, mixing, filling, and quality control
Trade secrets	Potentially relevant to process controls and supply-chain execution
Device patents	May apply to administration systems or compounders rather than the solution itself

The strongest practical barrier is sterile manufacturing. Amino-acid solutions must meet requirements for sterility, stability, container closure, particulate control, and assay consistency. Those requirements raise entry costs, but they do not create the pricing power associated with patented specialty pharmaceuticals.

When does TRAVASOL lose exclusivity?

TRAVASOL’s principal commercial exclusivity has already expired in practical terms. The product belongs to a mature injectable category with multiple amino-acid and parenteral-nutrition alternatives.

A conventional exclusivity timeline is therefore less relevant than the following market milestones:

Commercial milestone	Status
Novel-drug exclusivity	Not the basis of the product’s current position
Patent exclusivity	No commercially important remaining composition patent identified
Generic competition	Established category competition
Therapeutic substitution	Possible within amino-acid injectable products, subject to clinical and formulary controls
Market access	Determined by hospital contracts, availability, and price
Current protection	Manufacturing scale, quality record, supply reliability, and distribution

A competitor does not need to replicate a patent-protected mechanism or clinical indication. It needs FDA approval, compliant sterile production, suitable packaging, and commercial access to hospitals and nutrition-support providers.

How does the parenteral-nutrition market affect TRAVASOL demand?

Demand is linked to the number and acuity of hospitalized patients who cannot receive adequate enteral nutrition. Major demand centers include intensive-care units, oncology services, surgical departments, neonatal and pediatric care, gastrointestinal disorders, and patients with prolonged gastrointestinal dysfunction.

The market has several structural characteristics:

Enteral nutrition is preferred when the gastrointestinal tract is functional, limiting the addressable market for TPN.
TPN demand rises when critical illness, surgery, bowel obstruction, severe malabsorption, or gastrointestinal failure prevents adequate enteral intake.
Hospital pharmacists and nutrition-support teams control product selection.
Amino-acid solutions are frequently purchased as part of a broader nutrition portfolio.
Supply interruptions can shift demand rapidly to alternative concentrations, manufacturers, or compounded preparations.

Clinical guidelines generally favor enteral nutrition over parenteral nutrition when feasible, but parenteral nutrition remains necessary for selected patients. The American Society for Parenteral and Enteral Nutrition identifies parenteral nutrition as appropriate when oral or enteral feeding is not possible or does not meet nutritional requirements (McClave et al., 2016).

What market dynamics determine TRAVASOL pricing?

TRAVASOL operates in a price-sensitive hospital market. Its pricing is shaped by:

Group purchasing organization contracts.
Hospital system purchasing agreements.
Competitive bids from injectable-nutrition suppliers.
Product concentration and bag size.
Available inventory.
Wholesaler and distributor margins.
Shortage conditions.
Reimbursement and hospital budget controls.
Conversion costs for pharmacy compounding and administration.

The absence of a strong patent barrier places a ceiling on sustainable price increases. A supplier may obtain temporary pricing leverage during a shortage, but that leverage can weaken when competitors restore production or hospitals approve substitutions.

The product also competes indirectly with premixed parenteral-nutrition formulations and pharmacy-compounded solutions. A hospital may select a conventional amino-acid product because it offers formulation flexibility, or choose a premixed product to reduce compounding labor and error risk.

What is the financial trajectory of TRAVASOL?

Baxter does not separately report revenue, gross margin, unit volume, or operating profit for TRAVASOL 8.5% Without Electrolytes in its annual reports. The product is included within broader pharmaceutical products, infusion therapies, clinical nutrition, or hospital-product activities, depending on the company’s reporting structure and period.

Financial metric	Publicly disclosed for TRAVASOL 8.5% specifically?
Annual revenue	No
Revenue growth	No
Unit volume	No
Product gross margin	No
EBITDA	No
Hospital contract pricing	No
Product-level market share	No
Product-level R&D spending	No

Baxter’s broader financial trajectory has been influenced by portfolio restructuring, hospital demand, infusion products, manufacturing costs, inflation, supply-chain constraints, and business divestitures. These factors can affect TRAVASOL’s economics without revealing product-level performance.

The likely financial profile is that of a mature, low-growth hospital injectable:

Revenue growth is more likely to track utilization, price adjustments, and supply events than prescription expansion.
Gross margins depend heavily on manufacturing utilization and plant efficiency.
Product-level promotional spending is likely limited compared with branded specialty drugs.
Manufacturing disruptions can produce sharp short-term revenue volatility.
Long-term pricing power is constrained by generic and alternative supply.
The product can retain strategic value as part of a broader hospital-nutrition portfolio.

How exposed is TRAVASOL to drug shortages?

Shortage exposure is material because sterile injectables depend on a limited number of qualified manufacturing sites and specialized packaging operations. FDA has identified recurring shortages across sterile injectable categories, including products used in hospital care. A shortage may result from manufacturing deviations, raw-material constraints, quality investigations, demand spikes, or facility interruptions (U.S. Food and Drug Administration, 2024b).

For TRAVASOL, shortage exposure has two opposing effects:

Scenario	Commercial effect
Stable supply	Price competition and predictable hospital demand
Baxter disruption	Lost sales, substitution, and possible contract erosion
Industry-wide shortage	Temporary pricing leverage and higher utilization of available inventory
Competitor recovery	Reversion toward competitive pricing
Pharmacy compounding increase	Potential displacement of commercial product
Hospital stockpiling	Short-term shipment volatility followed by normalization

Shortage-driven revenue should not be treated as durable growth. Hospitals may qualify alternate suppliers during a disruption, creating a lasting risk that some volume does not return.

Which companies challenge TRAVASOL?

Competitive pressure comes from manufacturers of amino-acid injections, parenteral-nutrition components, premixed nutrition products, and pharmacy-compounded preparations. The competitive set can vary by country and by hospital contract.

Relevant competitor categories include:

Fresenius Kabi.
ICU Medical, including products historically associated with the Hospira portfolio.
B. Braun.
Bespak or other contract sterile-injectable suppliers.
Regional generic-injectable manufacturers.
Outsourcing facilities and hospital pharmacies.

Competition is generally based on availability, price, concentration, container format, contract status, and quality performance. No single competitor needs to match every TRAVASOL presentation if the hospital can substitute another amino-acid concentration or compound an equivalent nutrition regimen.

What generic entry risks exist for TRAVASOL?

Generic-entry risk is high in principle but does not necessarily imply immediate commercial displacement. Mature amino-acid injections already operate in a competitive market, and market entry depends on sterile manufacturing economics.

The principal risks are:

A new supplier enters with lower contract pricing.
An existing supplier expands capacity.
A hospital system standardizes on another amino-acid portfolio.
A competitor offers more favorable bag configurations.
A shortage accelerates formulary conversion.
A 503B outsourcing facility supplies a hospital during an interruption.

The main barriers are operational rather than patent-based. A new entrant must demonstrate reliable sterile production, regulatory compliance, validated processes, adequate capacity, and distribution reach. FDA approval alone does not guarantee meaningful hospital penetration.

What formulations are protected by TRAVASOL-related IP?

The conventional 8.5% amino-acid solution has limited formulation differentiation. Commercially relevant differentiation may instead involve:

Electrolyte-free versus electrolyte-containing presentations.
Amino-acid concentration.
Pediatric or neonatal formulations.
Premixed two-chamber or three-chamber bags.
Container materials.
Port configuration.
Shelf life and storage conditions.
Compatibility with automated compounding systems.
Reduced manipulation requirements.

These characteristics can create operational advantages but generally do not provide durable exclusivity unless protected by a specific patent, device claim, manufacturing process, or regulatory barrier.

What litigation and Paragraph IV challenges affect TRAVASOL?

No major publicly established patent litigation campaign or high-value Paragraph IV dispute is associated with TRAVASOL 8.5% Without Electrolytes as a mature amino-acid injection product.

The litigation risk is more likely to arise from:

Product liability claims.
Sterility or contamination events.
Manufacturing deviations.
Contract disputes.
Supply obligations.
Regulatory enforcement.
Hospital purchasing disputes.

Because the product lacks a high-value novel-molecule patent estate, a traditional innovator-versus-generic patent litigation framework has limited strategic importance. The more significant legal exposure is operational and regulatory.

How does TRAVASOL compare with competing parenteral-nutrition products?

Factor	TRAVASOL 8.5%	Premixed nutrition bag	Pharmacy-compounded amino-acid solution
Formulation flexibility	High	Lower	High
Preparation labor	Requires compounding or mixing	Lower	High
Supply dependence	Commercial manufacturer	Commercial manufacturer	Local or outsourcing facility
Patent protection	Limited	May include packaging or device IP	Usually limited
Hospital use	Component of individualized TPN	Standardized nutrition regimens	Customized or shortage-driven
Pricing pressure	High	Moderate to high	Variable
Shortage response	Can be substituted	May require different nutrition strategy	Can expand during shortages

TRAVASOL’s principal value is flexibility. A hospital can add electrolytes and other nutrients based on patient-specific requirements. That advantage competes against the labor savings and standardization of premixed products.

What is the geographic coverage of TRAVASOL?

The product is most commercially relevant in the United States, where Baxter has established hospital distribution and a recognized parenteral-nutrition portfolio. Product availability, formulation names, concentrations, regulatory status, and marketing authorization differ by jurisdiction.

International expansion is constrained by:

Country-specific product registrations.
Local sterile-manufacturing requirements.
Hospital procurement systems.
Reimbursement rules.
Import and serialization requirements.
Local competitors.
National shortage policies.

A U.S. label does not establish authorization in Europe, Canada, Japan, or other markets. Geographic revenue cannot be inferred from the U.S. product name alone.

How strong is the patent estate for TRAVASOL?

The patent estate is weak as a source of exclusivity but the commercial franchise can remain defensible through execution.

Dimension	Assessment
Active-ingredient protection	Weak or absent
Method-of-use protection	Limited
Formulation protection	Limited for the conventional product
Manufacturing barrier	Moderate to high
Regulatory compliance barrier	Moderate to high
Brand and hospital familiarity	Moderate
Supply-chain advantage	Potentially material
Long-term pricing power	Low
Substitution risk	High
Litigation leverage	Low

TRAVASOL is therefore an operational franchise, not a patent franchise. Its value depends on dependable production, regulatory compliance, customer contracts, and the ability to maintain supply during industry disruptions.

Key Takeaways

TRAVASOL 8.5% Without Electrolytes is a mature amino-acid injection used as a component of parenteral nutrition.
Baxter is the principal U.S. marketer identified in product labeling.
The product does not rely on meaningful remaining composition-of-matter exclusivity.
Orange Book and Paragraph IV dynamics are less important than sterile manufacturing and hospital contracting.
Product-specific revenue and margin are not separately disclosed by Baxter.
Financial performance likely follows hospital utilization, pricing, supply reliability, and shortage conditions.
Generic and therapeutic-substitution risk is high because the category is mature and price sensitive.
Manufacturing capability, quality systems, and distribution are more important barriers than patents.
Premixed parenteral-nutrition products and pharmacy-compounded solutions are important commercial substitutes.
Litigation risk is primarily regulatory, manufacturing, supply, and product-liability related rather than patent driven.

FAQs About TRAVASOL 8.5% Without Electrolytes

Is TRAVASOL 8.5% a complete TPN product?

No. It supplies amino acids and must generally be combined with dextrose, lipids, electrolytes, vitamins, trace elements, and other components to create a complete parenteral-nutrition regimen.

Can TRAVASOL 8.5% be substituted with another amino-acid injection?

Potentially, but substitution depends on concentration, patient requirements, hospital policy, pharmacy protocols, availability, and the treating clinician’s decision.

Does TRAVASOL 8.5% contain sodium or potassium?

The labeled product is without electrolytes. Electrolytes may be added separately as clinically indicated.

Is TRAVASOL 8.5% protected by a patent?

The mature conventional amino-acid formulation does not appear to have a commercially important remaining composition patent. Packaging, manufacturing, or device-related rights could differ by presentation and jurisdiction.

Does Baxter disclose TRAVASOL sales?

No. Baxter reports financial results at broader business-segment levels and does not separately disclose TRAVASOL 8.5% revenue, units, market share, or product margin.

References

Baxter Healthcare Corporation. (2021). TRAVASOL 8.5% clinical product information and prescribing information. U.S. Food and Drug Administration.
McClave, S. A., Taylor, B. E., Martindale, R. G., Warren, M. M., Johnson, D. R., Braunschweig, C., McCarthy, M. S., Davanos, E., Rice, T. W., Cresci, G. A., Gervasio, J. M., Sacks, G. S., Roberts, P. R., & Compher, C. (2016). Guidelines for the provision and assessment of nutrition support therapy in the adult critically ill patient. Journal of Parenteral and Enteral Nutrition, 40(2), 159-211.
U.S. Food and Drug Administration. (2024a). Approved drug products with therapeutic equivalence evaluations. FDA.
U.S. Food and Drug Administration. (2024b). Drug shortages. FDA.
Baxter International Inc. (2024). Annual report and Form 10-K. Baxter International.

US Patents:	0
Applicants:	1
NDAs:	1
DailyMed Link:	TRAVASOL 8.5% W/O ELECTROLYTES at DailyMed

TRAVASOL 8.5% W/O ELECTROLYTES Drug Patent Profile

When do Travasol 8.5% W/o Electrolytes patents expire, and when can generic versions of Travasol 8.5% W/o Electrolytes launch?

DrugPatentWatch^® Litigation and Generic Entry Outlook for Travasol 8.5% W/o Electrolytes

AI Deep Research

Questions you can ask:

Summary for TRAVASOL 8.5% W/O ELECTROLYTES

US Patents and Regulatory Information for TRAVASOL 8.5% W/O ELECTROLYTES

TRAVASOL 8.5% Without Electrolytes: Market Dynamics, Patent Position, and Financial Trajectory